Information Provided By:
Fly News Breaks for February 25, 2020
TBPH
Feb 25, 2020 | 07:51 EDT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Theravance Biopharma with a $55 price target following the company's "solid quarter of execution." The Street is underestimating the peak sales potential of Theravance's pipeline, and commercialization of these programs could drive upward earnings revisions, Chen tells investors in a research note. She sees 2020 as a "big year" for Theravance, with royalties from Trelegy Ellipta, increased cash flows from Yupelri, pipeline data readouts and additional product approvals.
News For TBPH From the Last 2 Days
There are no results for your query TBPH